From 2021 to 2023, overall hallucinogen use among Americans aged 12 and older remained stable at about 2.8%, but trends for individual substances diverged. LSD use declined from 0.88% to 0.58%, while ketamine use increased from 1.61% to 1.91%. Use of ecstasy/MDMA and tryptamines (including DMT) stayed steady, and PCP and Salvia divinorum remained rare. Hallucinogen use was concentrated among young adults and males, with higher odds among uninsured individuals and those below the federal poverty level. Substance-specific monitoring may better inform screening, prevention, and harm-reduction efforts than aggregate hallucinogen indicators.
After weekend ecstasy use, mood on Monday is lower than after non-use weekends. This effect is explained largely by more time spent in bed, which independently predicts lower mood. No differences were found in weekly depression or anxiety scores. The findings suggest that recovery-related behavior, not MDMA alone, may underlie post-use mood declines, though directionality cannot be determined.